Original Research
Recently published articles about Original Research
Original Research
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management
August 27, 2025
This study provides preliminary evidence that longitudinal use of an AI-enabled clinical decision support system can improve outcomes in MDD.
Original Research
N-acetylcysteine for Co-occurring PTSD and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial
August 27, 2025
Among individuals with PTSD and alcohol use disorder receiving CBT and either NAC or placebo, both groups had significant reductions in both PTSD symptom severity and alcohol use, with...
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to...
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Recent JCP Articles on Original Research
Clinical and Practical Psychopharmacology
The Superiority of Clozapine Over SGAs in Patients With Treatment-Resistant Schizophrenia
August 25, 2025
Clozapine is associated with many adverse effects. Given the findings that olanzapine and risperidone may be as good as clozapine in treatment-resistant schizophrenia (TRS), it may be worth trialing...
